Time-course and dose-response relationships of imperatorin in the mouse maximal electroshock seizure threshold model

Neuroscience Research

Volumn 59, Issue 1, 2007, Pages 18-22

  Luszczki, Jarogniew J ^a   Glowniak, Kazimierz ^a   Czuczwar, Stanislaw J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Imperatorin; Maximal electroshock seizure threshold test; Mice

Indexed keywords

PENTOSALEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CHRONOPHARMACOLOGY; CONTROLLED STUDY; CONVULSION; DOSE TIME EFFECT RELATION; DRUG DOSE INCREASE; DRUG EFFECT; ELECTRIC SHOCK; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; SEIZURE THRESHOLD; SYSTEMIC THERAPY;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTROSHOCK; MALE; MICE; PSORALENS; SEIZURES; TIME FACTORS;

EID: 34548041131     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2007.05.004     Document Type: Article

References (34)

1. Abad M.J., de las Heras B., Silvan A.M., Pascual R., Bermejo P., Rodriquez B., and Villar A.M. Effects of furocoumarins from Cachrys trifida on some macrophage functions. J. Pharm. Pharmacol. 53 (2001) 1163-1168
2. Baek N.I., Ahn E.M., Kim H.Y., and Park Y.D. Furanocoumarins from the root of Angelica dahurica. Arch. Pharm. Res. 23 (2000) 467-470
3. Bergendorff O., Dekermendjian K., Nielsen M., Shan R., Witt R., Ai J., and Sterner O. Furanocoumarins with affinity to brain benzodiazepine receptors in vitro. Phytochemistry 44 (1997) 1121-1124
4. Brodie M.J., and Schachter S.C. Fast facts. Epilepsy. Second ed. (2001), Health Press, Oxford, UK
5. Cai Y., Baer-Dubowska W., Ashwood-Smith M., and DiGiovanni J. Inhibitory effects of naturally occurring coumarins on the metabolic activation of benzo[a]pyrene and 7 12-dimethylbenz[a]anthracene in cultured mouse keratinocytes. Carcinogenesis 18 (1997) 215-222
6. Cai Y., Kleiner H., Johnston D., Dubowski A., Bostic S., Ivie W., and DiGiovanni J. Effect of naturally occurring coumarins on the formation of epidermal DNA adducts and skin tumors induced by benzo[a]pyrene and 7 12-dimethylbenz[a]anthracene in SENCAR mice. Carcinogenesis 18 (1997) 1517-1521
7. Chen I.S., Chang C.T., Sheen W.S., Teng C.M., Tsai I.L., Duh C.Y., and Ko F.N. Coumarins and antiplatelet aggregation constituents from Formosan Peucedanum japonicum. Phytochemistry 41 (1996) 525-530
8. Choi S.Y., Ahn E.M., Song M.C., Kim D.W., Kang J.H., Kwon O.S., Kang T.C., and Baek N.I. In vitro GABA-transaminase inhibitory compounds from the root of Angelica dahurica. Phytother. Res. 19 (2005) 839-845
9. Czuczwar S.J., and Patsalos P.N. The new generation of GABA enhancers potential in the treatment of epilepsy. CNS Drugs 15 (2001) 339-350
10. Dekermendjian K., Ai J., Nielsen M., Sterner O., Shan R., and Witt M.R. Characterisation of the furanocoumarin phellopterin as a rat brain benzodiazepine receptor partial agonist in vitro. Neurosci. Lett. 219 (1996) 151-154
11. Erlander M.G., and Tobin A.J. The structural and functional heterogeneity of glutamic acid decarboxylase: a review. Neurochem. Res. 16 (1991) 215-226
12. Gale K., and Iadarola M.J. Seizure protection and increased nerve-terminal GABA: delayed effects of GABA transaminase inhibition. Science 208 (1980) 288-291
13. Hinkle D.E., Wiersma W., and Jurs S.G. Applied Statistics for the Behavioral Science. Third ed. (1994), Houghton Mifflin Company, Boston, USA
14. Kawaii S., Tomono Y., Katase E., Ogawa K., and Yano M. Effect of coumarins on HL-60 cell differentiation. Anticancer Res. 20 (2000) 2505-2512
15. Kawaii S., Tomono Y., Ogawa K., Sugiura M., Yano M., Yoshizawa Y., Ito C., and Furukawa H. Antiproliferative effect of isopentenylated coumarins on several cancer cell lines. Anticancer Res. 21 (2001) 1905-1911
16. Kleiner H.E., Vulimiri S.V., Miller L., Johnson Jr. W.H., Whitman C.P., and DiGiovanni J. Oral administration of naturally occurring coumarins leads to altered phase I and II enzyme activities and reduced DNA adduct formation by polycyclic aromatic hydrocarbons in various tissues of SENCAR mice. Carcinogenesis 22 (2001) 73-82
17. Kleiner H.E., Reed M.J., and DiGiovanni J. Naturally occurring coumarins inhibit human cytochromes P450 and block benzo[a]pyrene and 7 12-dimethylbenz[a]anthracene DNA adduct formation in MCF-7 cells. Chem. Res. Toxicol. 16 (2003) 415-422
18. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96 (1949) 99-113
19. Löscher W., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs II. Maximal electroshock seizure models. Epilepsy Res. 8 (1991) 79-94
20. Löscher W., Jäckel R., and Müller F. Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model. Eur. J. Pharmacol. 163 (1989) 1-14
21. Luszczki J.J., and Czuczwar S.J. How significant is the difference between drug doses influencing the threshold for electroconvulsions?. Pharmacol. Rep. 57 (2005) 782-786
22. Luszczki J.J., and Czuczwar S.J. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog. Neuropsychopharm. Biol. Psychiat. 31 (2007) 529-538
23. Luszczki J.J., Borowicz K.K., Swiader M., and Czuczwar S.J. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44 (2003) 489-499
24. Luszczki J.J., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch.Pharmacol. 373 (2006) 169-181
25. Martin D.L., Martin S.B., Wu S.J., and Espina N. Regulatory properties of brain glutamate decarboxylase (GAD): the apoenzyme of GAD is present principally as the smaller of two molecular forms of GAD in brain. J. Neurosci. 11 (1991) 2725-2731
26. Murray R.D.H., Mendez J., and Brown S.A. The Natural Coumarins: Occurrence. Chemistry and Biochemistry (1982), Wiley, New York, NY
27. Oh H., Lee H.S., Kim T., Chai K.Y., Chung H.T., Kwon T.O., Jun J.Y., Jeong O.S., Kim Y.C., and Yun Y.G. Furocoumarins from Angelica dahurica with hepatoprotective activity on tacrine-induced cytotoxicity in Hep G2 cells. Planta Med. 68 (2002) 463-464
28. Okamoto T., Yoshida S., Kobayashi T., and Okabe S. Inhibition of concanavalin A-induced mice hepatitis by coumarin derivatives. Jpn. J. Pharmacol. 85 (2001) 95-97
29. Pae H.O., Oh H., Yun Y.G., Oh G.S., Jang S.I., Hwang K.M., Kwon T.O., Lee H.S., and Chung H.T. Imperatorin, a furanocoumarin from Angelica dahurica (Umbelliferae), induces cytochrome c-dependent apoptosis in human promyelocytic leukaemia HL-60 Cells. Pharmacol. Toxicol. 91 (2002) 40-48
30. Sancho R., Marquez N., Gomez-Gonzalo M., Calzado M.A., Bettoni G., Coiras M.T., Alcami J., Lopez-Cabrera M., Appendino G., and Munoz E. Imperatorin inhibits HIV-1 replication through an Sp1-dependent pathway. J. Biol. Chem. 279 (2004) 37349-37359
31. Suzdak P.D., Foged C., and Andersen K.E. Quantitative autoradiographic characterization of the binding of [3H]tiagabine (NNC 05-328) to the GABA uptake carrier. Brain Res. 647 (1994) 231-241
32. Wall M.E., Wani M.C., Manikumar G., Hughes T.J., Taylor H., McGivney R., and Warner J. Plant antimutagenic agents 3. Coumarins J. Nat. Prod. 51 (1988) 1148-1152
33. Wang C.C., Chen L.G., and Yang L.L. Inducible nitric oxide synthase inhibitor of the Chinese herb I Saposhnikovia divaricata (Turcz.) Schischk. Cancer Lett. 145 (1999) 151-157
34. White H.S., Watson W.P., Hansen S.L., Slough S., Perregaard J., Sarup A., Bolvig T., Petersen G., Larsson O.M., Clausen R.P., Frolund B., Falch E., Krogsgaard-Larsen P., and Schousboe A. First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anticonvulsant action among inhibitors of mGAT1 and mGAT2. J. Pharmacol. Exp. Ther. 312 (2005) 866-874